MedTrace Logo

AMSA and Amiodarone Study in Cardiac Arrest

NCT04997980 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 629

Last updated 2024-03-08

No results posted yet for this study

Summary

Investigators' aim is to assess whether the administration of amiodarone during resuscitation could cause a reduction of the values of the amplitude spectral area (AMSA).

Amiodarone is recommended for the treatment of cardiac arrest due to ventricular tachycardia/ventricular fibrillation (VT/VF) ( with a low level of recommendation cause of conflicting results. AMSA is a parameter expressing the amplitude of VF and it has been shown to predict defibrillation success and the return of spontaneous circulation (ROSC). No data are available so far about the impact of amiodarone administration on AMSA values.

Conditions

  • Out-Of-Hospital Cardiac Arrest

Interventions

DRUG

Amiodarone Injection

Sponsors & Collaborators

  • University of the Basque Country (UPV/EHU)

    collaborator OTHER

  • Oslo University Hospital

    collaborator OTHER

  • The Hospital of Vestfold

    collaborator OTHER

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Italy
  • Norway
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04997980 on ClinicalTrials.gov